Bullish
Pfizer's stock rises 1.6% after JPMorgan raises price target to $30.
Pfizer's stock experienced a 1.6% increase following JPMorgan's decision to raise its price target from $28 to $30, maintaining a neutral rating. This adjustment reflects confidence in Pfizer's strategic initiatives and recent developments.
Key points
- JPMorgan raises Pfizer's price target to $30, maintaining a neutral rating.
- FDA approves TUKYSA regimen for HER2-positive metastatic breast cancer.
- Pfizer plans to close penicillin unit in Italy, affecting approximately 330 jobs.
Sources
AI-generated from public news sources. Not financial advice.
